Abstract
Introduction
Ovarian cancer is associated with high mortality due to presentation at advanced stage and high recurrence following treatment with chemotherapy. Most of the prognostic variables in ovarian cancer, including stage and residual disease, are amenable for assessment only after surgery. Currently there are no established preoperative markers including, CA-125, that can predict overall survival in patients with ovarian cancer. The aim of our study was to evaluate the prognostic significance of the preoperative haematological markers platelet lymphocyte ratio (PLR) and neutrophil lymphocyte ratio (NLR) in patients with ovarian cancer.
Method
Preoperative PLR and NLR were evaluated in 235 patients undergoing surgery for ovarian cancer. The prognostic significance of both markers was then determined by both uni- and multivariate analytical methods.
Results
High preoperative PLR (p<0.001) and NLR (p=0.001) were significantly associated with poor survival using univariate Cox survival analysis. The median overall survival in patients with a PLR of <300 was 37.4 months (95%CI 26.1–48.7) and 14.5 months (95%CI 11.7–17.2) in those with a PLR of >300. PLR (p=0.03) but not NLR (p=0.575) retained its significance as a prognostic marker on multivariate Cox’s regression analysis, along with stage (p<0.001) and residual disease (p=0.015).
Conclusion
We have shown for the first time that PLR is a novel independent prognostic marker in patients with ovarian cancer.
Similar content being viewed by others
References
Cancer Research UK (2006) Ovarian cancer incidence statistics. Cancer Research UK. Available from: http://info.cancerresearchuk.org/cancerstats/types/ovary/incidence/index.htm
Horner MJ, Ries LAG, Krapcho M et al (eds) (2009) SEER cancer statistics review, 1975–2006. Available from: http://seer.cancer.gov/csr/1975_2006/
Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249
Marchetti C, Pisano C, Facchini G et al (2009) First-line treatment of advanced ovarian cancer: current research and perspectives. Exp Rev Anticancer Ther 10:47–60
Ozols RF (2006) Challenges for chemotherapy in ovarian cancer. Ann Oncol 17[Suppl 5]:v181–187
Gadducci A, Cosio S, Tana R, Genazzani AR (2009) Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 69:12–27
Bast RC Jr, Badgwell D, Lu Z et al (2005) New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15[Suppl 3]:274–281
Gupta D, Lis CG (2009) Role of CA125 in predicting ovarian cancer survival: a review of the epidemiological literature. J Ovarian Res 2:13
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899
Hefler LA, Concin N, Hofstetter G et al (2008) Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 14:710–714
Li AJ, Madden AC, Cass I et al (2004) The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol 92:211–214
Bozkurt N, Yuce K, Basaran M et al (2004) Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer. Obstet Gynecol 103):82–85
Bishara S, Griffin M, Cargill A et al (2008) Pretreatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 138:71–75
den Ouden M, Ubachs JM, Stoot JE, van Wersch JW (1997) Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours. Eur J Obstet Gynecol Reprod Biol 72:73–77
Cho H, Hur HW, Kim SW et al (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58:15–23
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444
Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A (2007) Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 18:171–182
Chen LL, Ye F, Lü WG et al (2009) Evaluation of immune inhibitory cytokine profi les in epithelial ovarian carcinoma. J Obstet Gynaecol Res 35:212–218
Fumagalli LA, Vinke J, Hoff W et al (2003) Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 26:394–402
Fogar P, Sperti C, Basso D et al (2006) Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 32:22–28
Menczer J, Schejter E, Geva D et al (1998) Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur J Gynaecol Oncol 19:82–84
Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L (2009) The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet 279:53–56
Zacharski LR, Memoli VA, Ornstein DL et al (1993) Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 85:1225–1230
Bastida E, Ordinas A, Giardina SL, Jamieson GA (1982) Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase. Cancer Res 42:4348–4352
Holmes CE, Levis JE, Ornstein DL (2009) Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis. Clin Exp Metastasis 26:653–661
Aliustaoglu M, Bilici A, Ustaalioglu BB et al (2010) The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol 27:1060–1065
Ong SL, Garcea G, Thomasset SC et al (2008) Ten-year experience in the management of gallbladder cancer from a single hepatobiliary and pancreatic centre with review of the literature. HPB (Oxford) 10:446–458
Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G et al (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxelcisplatin chemotherapy: a prospective study. BMC Cancer 10:50
Smith RA, Bosonnet L, Raraty M et al (2009) Preoperative platelet-lymphocyte ratio is an independent signifi cant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197:466–472
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Asher, V., Lee, J., Innamaa, A. et al. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol 13, 499–503 (2011). https://doi.org/10.1007/s12094-011-0687-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-011-0687-9